Michael Kolinsky
Cross Cancer Institute, Edmonton, Alberta, Canada · AHS-CCI · Cross Cancer Institute, Edmonton, AB Canada
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Kolinsky as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:06 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06439225 · Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response GenesCanadian Cancer Trials Group · recruiting · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer · study chair
- Ph2NCT06001125 · Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)AHS Cancer Control Alberta · terminated · Arthritis, Arthralgia · principal investigator
- Ph2NCT04354649 · Immune-Mediated Pathophysiology And Clinical Triage ProgramAHS Cancer Control Alberta · recruiting · Arthritis, Arthralgia · principal investigator
- Ph2NCT03385655 · Prostate Cancer Biomarker Enrichment and Treatment SelectionCanadian Cancer Trials Group · active not recruiting · Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:06 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.N Engl J Med · 2020340 citationsRCR 15.0
- 138 citationsRCR 10.4
- Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).Clin Cancer Res · 2022103 citationsRCR 6.4
- 77 citationsRCR 3.0
- 73 citationsRCR 4.5
- 61 citationsRCR 4.5
- Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.Eur J Cancer · 202216 citationsRCR 1.0